Soleno Therapeutics (SLNO) EBT (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly EBT of $34.9 million for Q1 2026, up 179.76% year-over-year from $12.5 million in Q1 2025, and down 19.48% quarter-over-quarter from $43.4 million in Q4 2025.
Soleno Therapeutics (SLNO) EBT (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported EBT for 14 consecutive years, with $34.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 179.76% year-over-year to $34.9 million; the TTM figure through Mar 2026 stood at -$181.8 million (up 50.23% YoY), while the FY2025 annual figure was -$53.5 million, up 79.34% from the prior year.
- EBT declined to $34.9 million in Q1 2026 per SLNO's latest filing, from $43.4 million in the prior quarter.
- Across five years, EBT topped out at $43.4 million in Q4 2025 and bottomed at -$173.9 million in Q2 2025.
- Historically, EBT has averaged -$48.0 million across 5 years, with a median of -$43.8 million in 2025.
- Annual changes were most pronounced in 2022 — EBT plunged 1986.87% — and 2026, when it soared 179.76%.
- Soleno Therapeutics' EBT stood at -$62.6 million in 2022, then surged by 81.09% to -$11.8 million in 2023, then plunged by 370.61% to -$55.7 million in 2024, then surged by 177.79% to $43.4 million in 2025, then retreated by 19.48% to $34.9 million in 2026.
- Business Quant data shows SLNO's EBT at $34.9 million in Q1 2026, $43.4 million in Q4 2025, and -$86.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 34.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.91 Mn |
| Dec 31, 2025 | 43.36 Mn |
| Sep 30, 2025 | -86.16 Mn |
| Jun 30, 2025 | -173.92 Mn |
| Mar 31, 2025 | -43.77 Mn |
| Dec 31, 2024 | -55.73 Mn |
| Sep 30, 2024 | -173.76 Mn |
| Jun 30, 2024 | -91.99 Mn |
| Mar 31, 2024 | -100.06 Mn |
| Dec 31, 2023 | -11.84 Mn |
| Sep 30, 2023 | -58.17 Mn |
| Jun 30, 2023 | -8.48 Mn |
| Mar 31, 2023 | -8.48 Mn |
| Dec 31, 2022 | -62.63 Mn |
| Sep 30, 2022 | -6.48 Mn |
| Jun 30, 2022 | -7.13 Mn |
| Mar 31, 2022 | -6.22 Mn |
| Dec 31, 2021 | -3.00 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Jun 30, 2021 | -11.70 Mn |